3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
81
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Brain Neoplasms
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Multiple Myeloma
4
HER2-positive Breast Cancer
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hematologic Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Wilms Tumor
1
Uterine Neoplasms
1
Urologic Neoplasms
1
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Thyroid Neoplasms
1
Thrombocytosis
1
Solid Tumors
1
Sarcoma, Synovial
1
Sarcoma
1
Interventions
Cyclophosphamide
38
Paclitaxel
22
Epirubicin
21
Trastuzumab
20
Docetaxel
20
Doxorubicin
19
Carboplatin
15
Radiotherapy
13
Taxes
11
Filgrastim
11
Neoadjuvant Therapy
9
Bevacizumab
9
Fluorouracil
8
pembrolizumab
7
Tamoxifen
7
Albumin-Bound Paclitaxel
7
Capecitabine
6
pertuzumab
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Lapatinib
5
130-nm albumin-bound paclitaxel
5
pegfilgrastim
4
Granulocyte Colony-Stimulating Factor
4
Cisplatin
4
Chemotherapy, Adjuvant
4
tipifarnib
3
eribulin
3
Surgical Procedures, Operative
3
Specimen Handling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Inflammatory Breast Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts